公开(公告)号：US20210172962A1

公开(公告)日：2021-06-10

申请号：US17172761

申请日：2021-02-10

Applicant: Roche Diagnostics Operations, Inc. ,  UNIVERSITEIT MAASTRICHT ,  AKADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Manuel Dietrich ,  Peter Kastner ,  Vinzent Rolny ,  Ulrich Schotten ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.

公开(公告)号：US20170227552A1

公开(公告)日：2017-08-10

申请号：US15581587

申请日：2017-04-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Roberto Latini ,  Serge Masson ,  Dirk Block ,  Christian Zaugg ,  Thomas Dieterle ,  Edelgard Kaiser ,  Johann Karl ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68

Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.